Virtu KCG Holdings LLC Takes $455,000 Position in PTC Therapeutics, Inc. (PTCT)

Virtu KCG Holdings LLC purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 24,823 shares of the biopharmaceutical company’s stock, valued at approximately $455,000. Virtu KCG Holdings LLC owned 0.07% of PTC Therapeutics at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. AXA acquired a new stake in shares of PTC Therapeutics in the first quarter valued at about $103,000. Nisa Investment Advisors LLC acquired a new stake in shares of PTC Therapeutics in the second quarter valued at about $125,000. Prudential Financial Inc. acquired a new stake in shares of PTC Therapeutics in the second quarter valued at about $201,000. American International Group Inc. increased its stake in shares of PTC Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 20,480 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 1,355 shares during the period. Finally, Laurion Capital Management LP acquired a new stake in shares of PTC Therapeutics in the first quarter valued at about $345,000. 81.30% of the stock is owned by institutional investors.

PTC Therapeutics, Inc. (PTCT) opened at 17.83 on Friday. The company’s market cap is $736.45 million. The firm has a 50-day moving average price of $19.59 and a 200 day moving average price of $16.40. PTC Therapeutics, Inc. has a one year low of $4.03 and a one year high of $22.00.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.89) by $0.45. The business had revenue of $47.96 million for the quarter, compared to analysts’ expectations of $28.78 million. PTC Therapeutics had a negative return on equity of 81.84% and a negative net margin of 88.43%. The business’s revenue was up 206.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.14) EPS. Equities analysts expect that PTC Therapeutics, Inc. will post ($2.35) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was posted by Markets Daily and is owned by of Markets Daily. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.themarketsdaily.com/2017/10/13/virtu-kcg-holdings-llc-takes-455000-position-in-ptc-therapeutics-inc-ptct.html.

Several brokerages recently commented on PTCT. Citigroup Inc. restated a “buy” rating and set a $28.00 target price on shares of PTC Therapeutics in a research report on Wednesday, September 27th. ValuEngine lowered PTC Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 7th. Barclays PLC restated a “hold” rating and set a $22.00 target price on shares of PTC Therapeutics in a research report on Friday, September 8th. Zacks Investment Research lowered PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Royal Bank Of Canada restated a “sector perform” rating on shares of PTC Therapeutics in a research report on Friday, September 29th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $17.11.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT).

Institutional Ownership by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply